ARCA biopharma is a clinical-stage biopharmaceutical company. Co.'s primary product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2 (AB201)) as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro™ (bucindolol hydrochloride) for the treatment of atrial fibrillation in patients with chronic heart failure. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.